Mifestone 25 | Mifestone 25 mg for Uterine Fibroids

Mifestone 25 is a low-dose, once-daily oral therapy designed to safely tone down uterine fibroids, Mifestone-25® harnesses the selective progesterone receptor-modulating action of mifepristone to relieve symptoms, shrink fibroid volume, reduce surgical intervention rates, and improve overall hematologic status. Manufactured by Health Care Pharmaceuticals, this tablet offers an effective, well-tolerated option for long-term management of symptomatic uterine leiomyomas making Mifestone 25 a trusted choice for women seeking non-surgical fibroid care.

Composition & Pharmacodynamics

• Active Ingredient: Mifepristone 25 mg per film-coated tablet

• Mode of Action:

  • Acts as a selective progesterone receptor modulator (SPRM) with predominant antagonistic effects on uterine progesterone receptors.

  • By blocking progesterone’s proliferative stimulus, it induces apoptosis of leiomyoma cells, reduces extracellular matrix deposition, and restores normal endometrial architecture.

  • Exhibits mild glucocorticoid receptor activity, contributing to anti-inflammatory benefits.

Clinical Indications of Mifestone 25

Mifestone-25® is indicated for the medical management of symptomatic uterine fibroids, specifically to:

• Reduce fibroid size and volume

• Control heavy menstrual bleeding (menorrhagia)

• Alleviate pelvic pain and pressure symptoms

• Delay or avoid hysterectomy

Key Statistic: In clinical studies, up to 98.14% of patients experienced a significant reduction in fibroid size.

Efficacy Highlights